That’s...not a great comparison. There are pretty good public health reasons NOT to be hasty in developing new antibiotics, regardless of the funding model.
I don’t think any new drug development (outside developing vaccine’s against a targeted that’s easy to vaccinate against because of prior research) is well described as ‘hasty’. While I think it’s worth arguing that developing antibiotics is stupid, the policy circles who care about the topic do think that it’s valuable to develop new antibiotics.
If they would change the regulations to allow for phage therapy and fund it I would also be okay with that, but they do neither.
That’s...not a great comparison. There are pretty good public health reasons NOT to be hasty in developing new antibiotics, regardless of the funding model.
I don’t think any new drug development (outside developing vaccine’s against a targeted that’s easy to vaccinate against because of prior research) is well described as ‘hasty’. While I think it’s worth arguing that developing antibiotics is stupid, the policy circles who care about the topic do think that it’s valuable to develop new antibiotics.
If they would change the regulations to allow for phage therapy and fund it I would also be okay with that, but they do neither.